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We investigated whether a polymorphism in codons 22
and 23 of the glucocorticoid (GC) receptor gene
[GAGAGG(GluArg) 3 GAAAAG(GluLys)] is associated
with altered GC sensitivity, anthropometric parame-
ters, cardiovascular risk factors, and sex steroid hor-
mones. In a subgroup of 202 healthy elderly subjects of
the Rotterdam Study, we identified 18 heterozygotes
(8.9%) for the 22/23EK allele (ER22/23EK carriers). In
the highest age group, the number of ER22/23EK carri-
ers was higher (67–82 years, 12.9%) than in the young-
est age group (53–67 years, 4.9%; P < 0.05). Two
dexamethasone (DEX) suppression tests with 1 and
0.25 mg DEX were performed, and serum cortisol and
insulin concentrations were compared between ER22/
23EK carriers and noncarriers. After administration of
1 mg DEX, the ER22/23EK group had higher serum
cortisol concentrations (54.8  18.3 vs. 26.4  1.4
nmol/l, P < 0.0001), as well as a smaller decrease in
cortisol (467.0  31.7 vs. 484.5  10.3 nmol/l, P <
0.0001). ER22/23EK carriers had lower fasting insulin
concentrations (P < 0.001), homeostasis model assess-
ment–insulin resistance (IR) (index of IR, P < 0.05),
and total (P < 0.02) and LDL cholesterol concentrations
(P < 0.01). Our data suggest that carriers of the 22/
23EK allele are relatively more resistant to the effects
of GCs with respect to the sensitivity of the adrenal
feedback mechanism than noncarriers, resulting in a
better metabolic health profile. Diabetes 51:3128–3134,
2002
Glucocorticoids (GCs) are important regulatorsin almost every tissue in the human body, andtheir effects are mediated by the GC receptor(GR) (1). A complete inability of GCs to exert
their effects on target tissues is probably not compatible
with life. However, several patients have been described
with partial forms of GC resistance. They show a wide
spectrum of clinical symptoms, such as hypertension,
hypokalemic alkalosis (2), fatigue, and hyperandrogenism
(3). Vingerhoeds et al. (2) reported a father and a son with
GC resistance, and from then until now 20 additional
patients and family members with this syndrome have
been described (4).
Besides these symptomatic patients with relative GC
resistance, within the normal population, a considerable
variability in the feedback sensitivity of the hypothalamo-
pituitary-adrenal (HPA) axis was also demonstrated (5).
The molecular mechanisms underlying this variation in GC
sensitivity are still largely unknown. In the symptomatic
patients with familial forms of GC resistance, missense
mutations in the ligand binding domain of the GR gene,
causing decreased ligand binding affinity, have been de-
scribed (6,7), as well as a deletion of four base pairs at the
boundary of exon 6 and intron 6, causing loss of a splice
site and a 50% reduction of receptor numbers per cell,
resulting also in GC resistance (8). Within the normal
population, several polymorphisms in the GR gene have
been reported (9). One of these polymorphisms consists of
a point mutation in codon 363 in exon 2 of the GR gene,
resulting in an asparagine-to-serine amino acid change,
and was shown to be associated with an increased sensi-
tivity to GCs in response to dexamethasone (DEX) (10).
Another polymorphism consists of two linked point muta-
tions separated by one base pair in codons 22 and 23 in
exon 2 of the GR gene. The mutations are located at cDNA
positions 198 and 200, respectively. The first mutation is
silent, changing codon 22 from GAG to GAA, both coding
for glutamic acid (E). The second mutation changes codon
23 from AGG to AAG, resulting in an amino acid change
from arginine (R) to lysine (K) (9). These mutations did
not seem to alter the activity of the GR during in vitro
experiments (11). However, the clinical relevance of this
polymorphism has not been studied. Within the context of
an ongoing population-based cohort study of diseases in
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the elderly (the Rotterdam Study), we investigated
whether there were any differences in vivo between ER22/
23EK carriers and noncarriers in the sensitivity of the HPA
axis to the overnight administration of 1 or 0.25 mg DEX,
as well as in some anthropometric parameters, cardiovas-
cular risk factors, and sex steroid hormone levels.
RESEARCH DESIGN AND METHODS
A total of 202 individuals participated in the study. Their age varied between
53 and 82 years (98 men and 104 women, with mean ages of 67.7  0.6 and
65.9  0.6 years, respectively). They were living in a suburb of Rotterdam, the
Netherlands. These subjects were participants in the Rotterdam Study, a
population-based cohort study (7,983 subjects) of the determinants of chronic
disabling diseases in the elderly, and they were selected at random. Subjects
with acute psychiatric or endocrine diseases, including diabetes treated with
medication, were not invited. Compared with all participants of the Rotterdam
study, there were no differences in age and sex distribution and cardiovascu-
lar risk factors. The subjects gave their written consent to participate in the
study, which received the approval of the Medical Ethics Committee of the
Erasmus University Medical School. To get more information about the
individual variability of the feedback sensitivity of the HPA axis, all 202
subjects were invited for a second DEX suppression test (DST) with a
lower-dose DEX (0.25 mg) 2.5 years later. A total of 149 subjects agreed to
participate in this second test (72 men and 77 women).
Anthropometric measurements The body weight, height, and waist-to-hip
ratio of the subjects were measured, and the BMI (in kg/m2) was calculated.
Blood pressure was measured in the sitting position at the right upper arm
with a random-zero sphygmomanometer.
DSTs The two DSTs were performed as described previously (5). In brief,
venous blood was obtained between 8:00 and 9:00 A.M., after an overnight fast,
for serum cortisol and insulin measurements. Participants were instructed to
ingest a tablet of 1 mg (and 0.25 mg for the second DST) DEX at 11:00 P.M.. The
next morning, fasting blood was drawn by venapuncture at the same time as
the previous morning. To check for compliance and possible abnormalities in
the metabolism of DEX, the DEX concentration was also measured in a
radioimmunoassay (RIA), using antiserum obtained from IgG Corporation
(Nashville, TN). Intra- and interassay variations were below 8.5 and 14.2%,
respectively.
Hormonal measurements Serum cortisol concentrations were determined
using RIA kits obtained from Diagnostics Products (Los Angeles, CA). Intra-
and interassay variations were below 8.0% and 9.5%, respectively. Circulating
insulin and cortisol-binding globulin (CBG) concentrations were determined
using commercially available RIAs (Medgenix Diagnostics, Brussels, Bel-
gium). Intra- and interassay variations were 8.0 and 13.7%, respectively.
Estradiol, androstenedione, and dehydroepiandrosterone-sulfate (DHEAS)
concentrations were determined using RIA kits obtained from Diagnostics
Products. Intra- and interassay variations, respectively, were as follows:
estradiol 7.0 and 8.1%, androstenedione 8.3 and 9.2%, and DHEAS 5.3 and 7.0%.
Sex hormone–binding globulin (SHBG) was assayed with a commercially
available immunoradiometric assay (Diagnostics Products); intra- and inter-
assay variations were 3.6 and 6.9%, respectively. Testosterone was measured
with a noncommercial RIA (intra- and interassay variations were 3.6 and
6.9%). Commercially available immunoradiometric assays were used for the
measurement of IGF-binding protein 1 (IGF-BP1; Diagnostic System Labora-
tories); intra- and interassay variations were 4.0 and 6.0%. Insulin resistance
(IR) and -cell function were estimated using the homeostasis model assess-
ment (HOMA), using the following previously described formula: (fasting
insulin [in mU/l]  fasting glucose [in mmol/l])/22.5 (12,13).
Biochemical measurements Glucose, total cholesterol, HDL cholesterol,
and triglycerides were measured using standard laboratory methods. LDL
cholesterol was calculated using the following formula: LDL cholesterol 
total cholesterol  ([triglycerides/5]  HDL cholesterol).
Genetic analysis Restriction fragment–length polymorphism (RFLP) analy-
sis was carried out to determine GR genotypes. DNA was extracted from
peripheral blood leukocytes using standard techniques. PCR amplification of
the GR gene was carried out using primer sequences and amplification
conditions, as described previously (9). The PCR products were digested with
1 unit Mnl I (New England Biolabs) at 37°C for 1 h. Mnl I cleaves at
5-CCTC(N)7-3 and at 3-GGAG(N)6-5. Fragments were visualized with
ethidium bromide on a 3% agarose gel (MP-Boehringer, Mannheim, Germany).
We reanalyzed the 18 heterozygous and 10 wild-type samples and found
identical genotypes.
Statistical analysis Data were analyzed using SPSS for Windows, release 9.0
(SPSS, Chicago, IL). Logarithmic transformations were applied to normalize
variables and to minimize the influence of outliers. Differences between the
ER22/23EK carriers and the noncarriers were adjusted for age and sex and
tested by ANCOVA using the general linear model procedure. A paired-
samples t test was used to compare changes in insulin concentrations before
and after the administration of DEX in all subjects. Results are reported as
means  SE.
Pearson’s correlation coefficients were used to calculate correlations
between cortisol, insulin, and cholesterol after correction for age, sex, and, if
necessary, BMI. The two age groups were chosen based on the median age
(67.02 years). Comparison of the frequencies of the genotypes between
different age groups was carried out using a 2 test. P values are two-sided
throughout, and P 	 0.05 was considered to indicate a significant difference.
RESULTS
RFLP analysis revealed in the study population of 202
subjects a total of 18 individuals (8.9%) who were het-
erozygous for the polymorphism in codon 22/23 (see also
Figs. 1 and 2). No individuals homozygous for this poly-
morphism were found in this group. The allele frequency
of the variant allele in this group was 4.5%. Genotype
distributions did not differ from those expected under
Hardy-Weinberg equilibrium conditions; however, we can-
not say this with absolute certainty, because we did not
find any homozygous ER22/23EK carriers. Sexes were
equally represented in the group of ER22/23EK carriers (9
men and 9 women), as well as in the group of noncarriers
(89 men and 95 women). The ER22/23EK carriers were 2.7
years older than noncarriers, and this difference did not
reach statistical significance (P  0.09) (Table 1). How-
ever, in the age-group between 67 and 82 years (n  101),
the number of ER22/23EK carriers was higher (12.9%) than
in the age-group between 53 and 67 years (n  101, 4.9%
ER22/23EK carriers; P 	 0.05). To rule out the influences
of differences in age, all parameters were adjusted for age.
No significant differences in anthropometric parameters or
blood pressure between the groups were present, as
shown in Table 1. At the second examination after 2.5
years, 149 of the initial 202 individuals participated (74%),
FIG. 1. Representative electrophoretic pattern of the GR22/23 geno-
type analyzed by PCR-RFLP from three subjects with the wild-type
ER22/23ER (WW, lane 1), heterozygous ER22/23EK (WM, lane 2), and
homozygous EK22/23EK (MM, lane 3) genotypes. ER22/23ER yielded a
163- and a 142-bp fragment; ER22/23EK appeared as three fragments of
177, 163, and 142 bp; whereas EK22/23EK consisted of a 177- and
163-bp fragment. (The homozygously affected individual was discov-
ered in a related population study in young children. Preliminary
investigations did not reveal specific anthropometric phenotypic
changes in this individual).
E.F.C. VAN ROSSUM AND ASSOCIATES
DIABETES, VOL. 51, OCTOBER 2002 3129
13 of whom were heterozygous for the codon 22/23
polymorphism. Also, in this group of ER22/23EK carriers,
the sexes were equally represented (six men and seven
women). The group of noncarriers now consisted of 66
men and 70 women.
Feedback sensitivity of the HPA axis. Table 2 shows
the concentrations of early morning serum cortisol con-
centrations before and after administration of 1 mg DEX,
the DEX concentration, and the cortisol suppression in
reaction to DEX (
 cortisol). Three subjects were taking
estrogen-containing medication, and because of the signif-
icant effect on CBG and, therefore, cortisol concentration,
they were excluded from the analysis (one of the ER22/
23EK carriers and two of the noncarriers) (14). One male
subject had not taken the 1 mg DEX tablet and was
excluded as well. There were no differences between the
noncarriers and the ER22/23EK carriers in fasting cortisol
concentrations. However, the cortisol concentrations after
the 1-mg DST were significantly higher in ER22/23EK
carriers than in noncarriers (54.8  18.3 and 26.4  1.4
nmol/l in ER22/23EK carriers and noncarriers, respec-
tively; P 	 0.0001). The absolute decrease of serum
cortisol concentrations after DEX, as well as the ratio of
post-DST cortisol to fasting cortisol, were significantly
different (
 cortisol: 467.0  31.7 nmol/l in ER22/23EK
carriers and 484.5 10.3 nmol/l in noncarriers, P	 0.0001;
ratio post-DEX to pre-DEX cortisol: 0.111  0.04 nmol/l in
ER22/23EK-carriers and 0.054  0.00 nmol/l in noncarri-
ers, P  0.003). The significant difference in post-DEX
cortisol concentrations was still present after inclusion of
the three estrogen-taking subjects. The actual DEX con-
centrations did not differ in both groups, so the higher
post-DEX cortisol levels and the smaller change in cortisol
after DEX in the ER22/23EK carriers were not caused by
differences in the metabolism of DEX. Also, fasting CBG
levels were not different between ER22/23EK carriers and
noncarriers (data not shown).
Also shown in Table 2 are the same parameters before
and after the administration of 0.25 mg DEX. Again, there
were no significant differences in fasting cortisol. The
post-DEX cortisol concentrations and the decrease in
cortisol concentrations after the administration of 0.25 mg
DEX, as well as the ratio of post-DEX to pre-DEX cortisol,
were not significantly different between ER22/23EK carri-
ers and noncarriers.
Insulin and glucose concentrations. Figure 3A shows
the fasting insulin concentrations before and after the
administration of 1 and 0.25 mg DEX, respectively. To be
certain that only the data from subjects with normal
carbohydrate tolerance were analyzed, subjects who had
developed either hyperinsulinemia or diabetes after inclu-
sion in the study (fasting insulin values 25 mU/l or
glucose concentrations of 7.8 mmol/l) were excluded
from this analysis (17 noncarriers excluded, n  167; 3
FIG. 2. Structure of the human GR gene,
mRNA, and protein and its functional
domains. The position of an arginine-to-
lysine change at codon 23, which results
from the G-to-A point mutation, and the
silent G-to-A point mutation at codon
22 are indicated. N-TERM, NH2-termi-
nal domain; DBD, DNA binding domain;
HBD, hormone binding domain.
TABLE 1
Anthropometric parameters and blood pressure in noncarriers (n  184) and ER22/23EK carriers (n  18) at baseline
Noncarriers ER22/23EK carriers
PMean SE Range Mean SE Range
Age (years) 66.5 0.44 53.0–81.6 69.2 1.68 53.5–82.4 0.09
Height (cm) 17.0 0.01 146–189 16.9 0.02 152–175 0.85
Weight (kg) 74.7 1.15 45.8–121.0 71.9 1.97 43–89.9 0.69
BMI (kg/m2) 26.4 0.28 16.4–43.1 25.4 0.85 16.4–32.5 0.25
WHR 0.92 0.01 0.66–1.12 0.94 0.02 0.75–1.08 0.62
SBP (mmHg) 138.9 1.42 99–185 140.2 5.03 96–178 0.86
DBP (mmHg) 74.7 0.73 48–97 77.1 2.95 44–97 0.42
Test for the difference between noncarriers and ER22/23EK carriers. All parameters were log transformed and, with the exception of age,
adjusted for age. DBP, diastolic blood pressure; SBP, systolic blood pressure; WHR, waist-to-hip ratio.
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ER22/23EK carriers excluded, n  15 at the first examina-
tion). In these 182 subjects together, a significant increase
in insulin concentrations in response to the administration
of 1 mg DEX was noted (11.5  5.15 mU/l before and
17.2  8.41 mU/l after DEX administration, respectively;
P 	 0.001). There were no differences in this increase in
serum insulin concentrations between the control group
and the ER22/23EK carriers (5.7  0.6 vs. 5.5  1.3 mU/l).
The fasting insulin concentrations tended to be lower in
ER22/23EK carriers than in noncarriers (P  0.06) (Fig.
3A). The same applied to the fasting serum insulin levels
measured after 1 mg DEX (P  0.07). These differences in
post-DEX insulin concentrations were not caused by dif-
ferences in DEX concentrations between the two groups.
Fasting glucose concentrations were not different between
the noncarriers and ER22/23EK carriers (5.71  0.05 vs.
5.69  0.16 mmol/l, respectively).
At second examination, 2.5 years later, the fasting
insulin levels in ER22/23EK carriers were significantly
lower than in the noncarriers (P 	 0.001). Insulin levels
decreased in the total group of 115 subjects after the
administration of 0.25 mg DEX (14.7  0.45 before and
13.9  0.50 mU/l after DEX administration, respectively;
P 	 0.01). There were no differences in this decrease in
insulin levels between the noncarriers and the ER22/23EK
carriers. After the administration of 0.25 mg DEX insulin
concentrations were not significantly different between
the ER22/23EK carriers and the noncarriers (P  0.11).
Baseline (fasting) glucose levels tended to be lower in the
ER22/23EK carriers than in the noncarriers (5.3 0.20 and
5.6 0.06 mmol/l, respectively; P 0.07). To assess IR and
insulin secretion, we used the HOMA-IR and HOMA for
-cell function (HOMA-B) index, respectively. As shown in
Fig. 3B, at first examination, ER22/23EK carriers had
significantly lower HOMA-IR scores (2.3  0.33) than
noncarriers (3.0  0.11, P 	 0.05). At the second measure-
ment, the same pattern of HOMA-IR was observed (2.4 
0.39 vs. 3.8  0.14 in ER22/23EK carriers and noncarriers,
respectively; P 	 0.01). HOMA-B scores tended to be
lower in ER22/23EK carriers compared with noncarriers at
both observations (84.8  11.6 and 108.2  3.5 for carriers
and noncarriers, P 	 0.06; and, at second examination,
119.0  17.4 vs. 148.6  4.7 carriers and noncarriers, P 	
0.07).
Risk factors for coronary heart disease and diabetes.
In Table 3, serum concentrations of IGF-BP1, total choles-
terol, LDL cholesterol, HDL cholesterol, and triglycerides
are shown. There were no differences between noncarriers
and ER22/23EK carriers in IGF-BP1 levels or in HDL
cholesterol and triglyceride concentrations. However, to-
tal cholesterol levels were significantly lower in ER22/
23EK carriers than in noncarriers (6.86  0.09 vs. 6.12 
0.25 mmol/l for noncarriers versus ER22/23EK carriers,
FIG. 3. A: Fasting insulin concentrations in noncarriers (n  167) and
ER22/23EK carriers (n  15) before 1 mg DEX at first examination.
Insulin concentrations tended to be lower in ER22/23EK carriers than
noncarriers (P  0.06). The right column shows fasting insulin concen-
trations in noncarriers (n  105) and ER22/23EK carriers (n  10) at
second examination (2.5 years later). Fasting insulin concentrations
were significantly lower in ER22/23EK carriers (P < 0.001). B:
HOMA-IR scores at baseline and at second examination 2.5 years later
in noncarriers and ER22/23EK carriers. At both measurements ER22/
23EK carriers were significantly less insulin resistant. All parameters
were log transformed and adjusted for age. Subjects with fasting
insulin >25 mU/l or fasting glucose >7.8 mmol/l were excluded from the
calculation; 3 ER22/23EK carriers and 17 noncarriers were excluded
from the first test and 3 ER22/23EK carriers and 31 noncarriers were
excluded from the second test. f, noncarriers; , ER22/23EK carriers
TABLE 2
Cortisol and DEX concentrations before and after 1 and 0.25 mg DEX, respectively, in noncarriers (n  181 at first examination and
n  136 at second examination) and in ER22/23EK carriers (n  17 at first examination and n  13 at second examination)
Noncarriers ER22/23EK carriers
PMean SE Range Mean SE Range
1 mg DST
Fasting cortisol (nmol/l) 514.8 10.7 41–981 521.8 24.9 308–717 0.56
Post-DEX cortisol (nmol/l) 26.4 1.4 2–187 54.8 18.3 11–265 	0.0001

 cortisol (nmol/l) 484.5 10.3 39–856 467.0 31.7 138–674 	0.0001
DEX (nmol/l) 7.40 0.27 0.8–18.4 6.90 0.85 1.2–12.9 0.26
0.25 mg DST
Fasting cortisol (nmol/l) 545.3 12.4 47–914 527.2 30.3 325–710 0.78
Post-DEX cortisol (nmol/l) 259.5 12.4 14–630 267.5 31.3 83–418 0.57

 cortisol (nmol/l) 285.8 13.5 64–765 259.7 40.7 31–507 0.23
DEX (nmol/l) 2.85 0.13 0.1–8.7 2.88 0.52 0.6–7.1 0.69
Test for the difference between noncarriers and ER22/23EK carriers. All parameters were log transformed and adjusted for age and sex. Three
subjects were taking estrogen-containing medication and were excluded from the analysis (one ER22/23EK carrier and two noncarriers). One
noncarrier had not taken the 1-mg DEX tablet and was also excluded for that analysis.
E.F.C. VAN ROSSUM AND ASSOCIATES
DIABETES, VOL. 51, OCTOBER 2002 3131
P 0.02), as well as LDL cholesterol levels (5.11 0.08 vs.
4.31  0.25 mmol/l in noncarriers versus ER22/23EK
carriers, P 	 0.01) At the second examination after 2.5
years, serum cholesterol concentrations were again lower
(total cholesterol: 6.61 vs. 5.64 mmol/l in noncarriers
versus ER22/23EK carriers, P 0.01; LDL cholesterol: 4.87
vs. 3.87 mmol/l in noncarriers versus ER22/23EK carriers,
P 	 0.01 [not shown in table]).
Sex hormones. Table 4 shows the fasting concentrations
of sex hormones for men and women separately. No
differences between the noncarriers and the ER22/23EK
carriers in the concentrations of estradiol, SHBG, andro-
stenedione, DHEAS, or testosterone were detected. Again,
the three subjects who were taking estrogen-containing
medication were excluded from the analysis (one female
ER22/23EK carrier and two female noncarriers).
Correlations. The degree of cortisol suppression after 1
and 0.25 mg DEX positively correlated with fasting insulin
(r  0.19, P 	 0.02; and r  0.22, P 	 0.03, respectively)
and HOMA-IR (r  0.21, P 	 0.01; and r  0.23, P 	 0.02,
respectively), after adjustment for age and sex. These
correlations also persisted after additional correction for
BMI (Fig. 4). No correlations were found between a
decrease in cortisol and insulin response, total HDL and
LDL cholesterol, triglycerides, or HOMA-B scores. Base-
line insulin concentrations correlated positively with trig-
lycerides (r  0.31, P 	 0.0001), whereas an inverse
relation was found with HDL cholesterol (r  0.24, P 	
0.005).
DISCUSSION
In this population study in the elderly involving 202
individuals, we found 18 subjects who were heterozygous
for the ER22/23EK polymorphism (8.9%). Genotype distri-
bution was in Hardy-Weinberg equilibrium, as far as we
can say without finding any homozygous ER22/23EK car-
riers, which suggests that this sample was random. The
ER22/23EK carriers had higher serum concentrations of
cortisol and a smaller decrease in cortisol concentrations
after the administration of 1 mg DEX than noncarriers. We
would have expected to find a slight resistance more easily
in a 0.25-mg DST than in a 1-mg test. We indeed found the
same pattern of smaller decrease in cortisol and higher
post-DEX cortisol levels in ER22/23EK carriers compared
with noncarriers in the 0.25-mg DST. However, it was not
significant, possibly because of the lower number of
subjects who participated in the second test. Furthermore,
ER22/23EK carriers tended to have lower insulin levels
before and after a 1-mg DST. These data were partially
confirmed 2.5 years later with a 0.25-mg DST. Fasting
insulin concentrations were again lower in ER22/23EK
carriers than in noncarriers, and fasting glucose levels
tended to be lower in ER22/23EK carriers as well. In line
with these data, HOMA-IR values were lower in ER22/
23EK carriers, which indicates that they are more sensitive
to insulin. These observations suggest that this polymor-
phism in the GR gene is associated with a slight resistance
of the feedback regulation of the HPA axis. Furthermore,
cortisol suppression after DEX correlated, in all individu-
als studied together, with fasting insulin and HOMA-IR,
which was still significant after adjustment for BMI.
This relative resistance also results in a lower effect of
cortisol on glucose metabolism, resulting in slightly lower
glucose concentrations, as well as lower insulin levels.
This favorable metabolic profile is supported by the ob-
servation that total and LDL cholesterol concentrations
were significantly lower in the ER22/23EK group than in
the group of noncarriers. This was confirmed at the
second examination. These lower cholesterol concentra-
tions can possibly be partially explained by a reduced
TABLE 3
Risk factors for coronary heart disease and diabetes at first examination in noncarriers (n  184) and ER22/23EK carriers (n  18)
Noncarriers ER22/23EK carriers
PMean SE Range Mean SE Range
IGF-BP1 (g/l) 19.3 1.59 1–154 18.8 2.91 2.0–43.1 0.57
Total cholesterol (mmol/l) 6.86 0.09 2.80–10.32 6.12 0.25 4.31–7.41 0.02
LDL cholesterol (mmol/l) 5.11 0.08 0.91–8.31 4.31 0.25 2.65–6.09 0.01
HDL cholesterol (mmol/l) 1.36 0.03 0.72–2.51 1.43 0.14 0.84–2.83 0.63
Triglycerides (mmol/l) 1.91 0.07 0.47–7.42 1.93 0.33 0.76–7.00 0.67
Test for the difference between noncarriers and ER22/23EK carriers. All parameters were log transformed and adjusted for age.
TABLE 4
Hormones at first examination in male (n  89) and female (n  93) noncarriers and in male (n  9) and female (n  8) ER22/23EK
carriers
Men Women
Noncarriers ER22/23EK carriers Noncarriers ER22/23EK carriers
Mean SE Mean SE P Mean SE Mean SE P
Estradiol (pmol/l) 108.0 5.26 88.8 22.8 0.53 82.8 5.39 85.8 17.1 0.79
SHBG (nmol/l) 50.5 2.23 44.0 6.74 0.83 55.4 2.74 62.5 7.99 0.56
Androtenedione (nmol/l) 6.47 0.28 6.26 0.69 0.82 4.45 0.23 4.59 0.88 0.95
DHEAS (mmol/l) 3.97 0.24 3.80 0.46 0.76 2.38 0.49 2.54 0.16 0.92
Testosterone (nmol/l) 20.2 0.56 21.9 1.70 0.36 1.37 0.06 2.03 0.71 0.20
Shown are test results for the difference between noncarriers and ER22/23EK carriers. All parameters were log transformed. Three subjects
were taking estrogen-containing medication and were excluded from the analysis (one female ER22/23EK carrier and two female
noncarriers).
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cortisol effect. GCs have been demonstrated to influence
cholesterol levels by several mechanisms, such as regula-
tion of the uptake of LDL by the liver (15) and influencing
human adipose tissue lipoprotein lipase gene expression
(16). These outcomes of a relative GC resistance, together
with the lower insulin and total and LDL cholesterol and
slightly lower serum glucose concentrations, indicate that
ER22/23EK carriers have a healthier metabolic profile than
noncarriers. In this respect, our observation of a signifi-
cantly higher percentage of ER22/23EK carriers in the
older age-group supports the finding of a beneficial meta-
bolic effect of this GR polymorphism.
We found no other differences between the genotypes in
anthropometric parameters, blood pressure, and serum
levels of IGF-BP1, HDL cholesterol, triglycerides, or sex
hormones. In particular, this last observation is probably
in line with the fact that the ER22/23EK polymorphism in
the GR gene is associated with a very mild degree of
resistance, because other features previously described in
patients with symptomatic GC resistance (2,3), such as
hypertension and hypokalemia (related to compensatory
adrenocorticotropic hormone–mediated mineralocorti-
coid overproduction) or acne and a male pattern of
baldness (related to overproduction of adrenal andro-
gens), were not observed. We have previously reported
(17) five patients from our endocrine clinic who were
diagnosed with cortisol resistance. At that time, to get a
first impression of the effect of the ER22/23EK polymor-
phism, we had only genotyped 129 of the group of 216
subjects who underwent a DST. After completing the
genotyping for the ER22/23EK polymorphism of the whole
group, we report now subtle cortisol resistance, which is
associated with this polymorphism. In our previous publi-
cation, we reported that 3 of the 129 genotyped individuals
had post-DEX cortisol values 140 nmol/l. This cutoff
value is clinically used to screen for Cushing’s syndrome,
but it seems less useful for studying cortisol sensitivity in
the normal population. In the present study, we show that
the 18 ER22/23EK carriers had a significantly smaller mean
cortisol response to DEX, indicating a slight resistance to
the negative feedback of cortisol. We also reported that
two of five patients, who had a symptomatic cortisol-
resistance syndrome, carried the ER22/23EK polymor-
phism (17). We cannot say whether this polymorphism
was involved in the etiology of the syndrome, but it is
possible that it was at least a factor, together with other
causative factors.
Previously, we reported a polymorphism located in
codon 363 in exon 2 of the GR, which was associated with
an increased sensitivity to cortisol (10). The number of
N363S carriers was not significantly different between the
groups of ER22/23EK carriers and noncarriers (1 [5.5%] vs.
12 [6.5%] N363S carriers, P 0.32). Moreover, exclusion of
the N363S carriers did not alter the results.
In transient transfection assays in COS-1 cells, de Lange
et al. (11) did not find differences in the way the 23K
variant receptor regulated transcription from a number of
different promoters. Although the polymorphism is not
located in the core of the 1 transactivation domain, which
is variably defined as amino acid 77–262 (18) or 98–305
(19), it is possible that the effects described here are
caused by altered interactions with other proteins that do
not play a role in the COS-1 system.
In summary, in this study we observed that subjects
who were heterozygous for the 22/23EK allele had
significantly higher post-DEX cortisol concentrations, a
smaller decrease in cortisol concentrations, lower insu-
lin, slightly lower fasting glucose levels, and slightly
lower post-DEX insulin levels than subjects without this
GR variant. Furthermore, ER22/23EK carriers had lower
total and LDL cholesterol levels and were overrepre-
sented in the older age-group. These data suggest that
ER22/23EK carriers are relatively more “cortisol resis-
tant” than noncarriers, which results in a better meta-
bolic health profile. The exact mechanism through
which the ER22/23EK variant of the GC receptor estab-
lishes these favorable effects remains unclear and is one
of the subjects of our ongoing research.
FIG. 4. Correlation between the decrease in serum cortisol concentrations after 0.25 mg DEX and fasting insulin (A) and HOMA-IR (B). A total
of 179 individuals participated in the study. Data were adjusted for age, sex, and BMI. Subjects who had taken estrogen-containing medication
or with fasting insulin >25 mU/l or fasting glucose >7.8 mmol/l were excluded from the analysis.
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